| Blumenschein, George R |
NCI-2018-01836, NCT00494182: Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
|
|
| Active, not recruiting | 2 | 48 | US | Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sorafenib, BAY 43-9006 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma | 12/25 | 12/25 | | |
|
| Withdrawn | 1/2 | 75 | Europe, US | IMC-C103C, Atezolizumab, TECENTRIQ | Immunocore Ltd | Select Advanced Solid Tumors | 09/23 | 09/23 | | |
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 159 | US, RoW | AU-007, Aldesleukin, Avelumab | Aulos Bioscience, Inc. | Advanced Solid Tumor, Metastatic Cancer | 08/25 | 09/25 | | |
| Recruiting | 1/2 | 182 | Europe, Canada, US, RoW | TAK-280 | Takeda, Takeda Development Center Americas, Inc. | Unresectable Locally Advanced or Metastatic Cancer | 02/25 | 07/26 | | |
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 258 | Europe, US, RoW | TAK-186, MVC-101 | Takeda | Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer | 09/25 | 11/26 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer |
|
|
| Recruiting | 1/2 | 237 | US | REGN5093-M114, Cemiplimab | Regeneron Pharmaceuticals | Advanced NSCLC | 02/30 | 02/30 | | |
NCT02321501: Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 37 | US | Ceritinib, LDK 378, LDK378, Zykadia, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Laboratory Biomarker Analysis, Pharmacological Study | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC V7, Stage IV Lung Non-Small Cell Cancer AJCC V7 | 12/24 | 12/24 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
| Recruiting | 1 | 275 | Europe, US | SGN-EGFRd2 | Seagen Inc. | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 07/27 | 09/28 | | |
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination |
|
|
| Recruiting | N/A | 10000 | Europe, Canada, US | | Adaptimmune | Solid and Hematological Malignancies | 11/25 | 11/25 | | |
| GREILLIER, Laurent |
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies |
|
|
| Recruiting | 4 | 500 | Europe | Bio-bank repository, Quality of Life (QoL), G-Code | Groupe Francais De Pneumo-Cancerologie | Non Small Cell Lung Cancer, Lung Cancer | 08/26 | 08/28 | | |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % |
|
|
| Active, not recruiting | 3 | 349 | Europe | Pembrolizumab, Pembrolizumab and Chemotherapy drugs | University Hospital, Brest, Groupe Français de Pneumo-Cancérologie | Non-small-cell Lung Cancer | 12/25 | 12/25 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents |
|
|
| Active, not recruiting | 2 | 43 | Europe | Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080 | MedSIR, Merck Sharp & Dohme LLC | Metastatic Thymic Carcinoma, Thymoma Type B3 | 07/24 | 01/26 | | |
| Active, not recruiting | 2 | 55 | Europe | Nivolumab, BMS-936558-01 | European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation | Thymoma Type B3, Thymic Carcinoma | 12/23 | 07/24 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 80 | Europe, RoW | Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736 | Centre Leon Berard, Groupe Français de Pneumo-Cancérologie | Large Cell Neuroendocrine Carcinoma of the Lung | 09/28 | 09/29 | | |
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | Europe | Repotrectinib | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon | NSCLC Stage IV, NSCLC, Stage III | 09/31 | 09/31 | | |
SPORADIC, NCT06656598: Study Evaluating the Efficacy and the Tolerance of Immunochemotherapy and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients with Stage III Lung Cancer |
|
|
| Not yet recruiting | 2 | 152 | Europe | Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance) | Intergroupe Francophone de Cancerologie Thoracique | Stage III NSCLC | 09/28 | 01/32 | | |
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 186 | Europe, Canada, US, RoW | inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta | iTeos Therapeutics, iTeos Belgium SA | Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | 04/25 | 05/25 | | |
| Recruiting | 2 | 70 | Europe, US | IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy | Innate Pharma, Innate Pharma SA | Non Small Cell Lung Cancer | 06/25 | 09/26 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
| Recruiting | 2 | 68 | Europe | Adagrasib | ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc. | NSCLC Stage IV, KRAS P.G12C | 10/25 | 03/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
| Recruiting | 2 | 550 | Europe | Durvalumab | UNICANCER, AstraZeneca | Small Cell Lung Carcinoma | 01/27 | 03/29 | | |
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 44 | Europe | Brigatinib, Durvalumab | ETOP IBCSG Partners Foundation, Takeda | NSCLC, Stage III, ALK-rearrangement | 09/24 | 09/24 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1 | 180 | Europe, US, RoW | IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan | IDEAYA Biosciences | Solid Tumor | 12/26 | 03/27 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab |
|
|
| Active, not recruiting | N/A | 200 | Europe | Data collection | Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb | Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm | 04/25 | 04/25 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
REAL-MOOV-LUNG, NCT04934865: Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : |
|
|
| Active, not recruiting | N/A | 240 | Europe | Patients treated for their lung cancer. | Institut Curie | Lung Cancer | 10/26 | 10/26 | | |
| Active, not recruiting | N/A | 413 | Europe | Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L) | Groupe Francais De Pneumo-Cancerologie, AstraZeneca | Non-Small Cell Lung Cancer | 06/27 | 06/27 | | |
| Chen, Ray-Jade |
NCT03801512: Comparing the Efficacy of Steroid, Acupuncture and Platelet Rich Plasma Injection in Patients with Sciatica |
|
|
| Recruiting | N/A | 90 | RoW | Steroid, Acupuncture, Platelet Rich Plasma | Taipei Medical University Hospital | Sciatica | 05/25 | 05/25 | | |
| Sue, Yuh-Mou |
| Recruiting | 3 | 2000 | Europe, Canada, RoW | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo | The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center | Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease | 06/27 | 12/27 | | |
|
| Recruiting | 3 | 685 | Europe, Canada, US, RoW | Renal Autologous Cell Therapy (REACT), Sham Comparator | Prokidney, Iqvia Pty Ltd, PPD | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 02/27 | 02/27 | | |
| Chang, Chuen-Chau |
NCT05756933: Arterial Waveform Analysis for Predicting Post-induction Hypotension |
|
|
| Active, not recruiting | N/A | 50 | RoW | | Taipei Medical University, National Science Council, Taiwan | Hypotension on Induction | 11/23 | 04/24 | | |
| Recruiting | N/A | 50 | RoW | ArteVu | Cardio Ring Technologies, Inc. Taiwan Branch, Taipei Medical University Hospital | Blood Pressure | 03/22 | 06/22 | | |
| Kang |
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention | Takeda, Takeda Development Center Americas, Inc. | Ulcerative Colitis, Crohn's Disease | 08/31 | 08/31 | | |
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 3 | 750 | Europe, Canada, Japan, US, RoW | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine | Stichting European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 06/33 | 08/40 | | |
NCT06592495: Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315 |
|
|
| Not yet recruiting | 1 | 52 | NA | Period 1, Period 2, Period 3, Period 4 | Daewoong Pharmaceutical Co. LTD. | Healthy Volunteers | 01/25 | 10/25 | | |
NCT05555212: To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 72 | RoW | QLH11811 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT06734858: Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms |
|
|
| Recruiting | N/A | 110 | RoW | SAT014, Control | S-Alpha Therapeutics, Inc. | Post-traumatic Stress Disorder, Adjustment Disorders | 07/25 | 10/25 | | |
NCT06741475: Feasibility Study of Caregiver-Assist Strategy Training |
|
|
| Not yet recruiting | N/A | 30 | RoW | Caregiver-Assist Strategy Training, CaST, Education | Taipei Medical University | Stroke | 06/27 | 12/27 | | |
CAR-ST, NCT06754566: A Caregiver-Assisted Rehabilitation With Strategy Training () for Stroke Patients |
|
|
| Not yet recruiting | N/A | 261 | RoW | Caregiver-Assisted Rehabilitation with Strategy Training, CAR-ST, Strategy Training, ST, Education | Taipei Medical University | Stroke | 06/28 | 12/28 | | |
| Wu, Mai-Szu |
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD |
|
|
| Completed | 3 | 141 | RoW | Ferric citrate, Placebo | Panion & BF Biotech Inc. | Anemia of Chronic Kidney Disease | 10/22 | 12/22 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 3 | 685 | Europe, Canada, US, RoW | Renal Autologous Cell Therapy (REACT), Sham Comparator | Prokidney, Iqvia Pty Ltd, PPD | Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 02/27 | 02/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT02933827: Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease |
|
|
| Completed | 1/2 | 39 | RoW | ELIXCYTE | UnicoCell Biomed CO. LTD, Protech Pharmaservices Corporation (PPC) | Moderate to Severe Chronic Kidney Disease | 04/19 | 06/23 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Wu, Meng-Huang |
NCT03168802: MRgFUS and RFA for Treatment of Facet-joint Osteoarthritis Low Back Pain |
|
|
| Recruiting | N/A | 100 | RoW | MRgFUS ablation, Radiofrequency ablation | Taipei Medical University Hospital | Chronic Low Back Pain, Facet Joint Syndrome | 11/25 | 11/25 | | |
NCT03801512: Comparing the Efficacy of Steroid, Acupuncture and Platelet Rich Plasma Injection in Patients with Sciatica |
|
|
| Recruiting | N/A | 90 | RoW | Steroid, Acupuncture, Platelet Rich Plasma | Taipei Medical University Hospital | Sciatica | 05/25 | 05/25 | | |
| Coordinator, Site |
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
|
|
| Completed | 4 | 30 | US | CREON, Pancrelipase | AbbVie | Cystic Fibrosis, Chronic Pancreatitis | 07/23 | 08/23 | | |
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections |
|
|
| Completed | 4 | 73 | Europe, RoW | BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | AbbVie | Facial Corrections, Facial Lines | 10/23 | 10/23 | | |
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
|
|
| Completed | 4 | 52 | US | Oxybutynin, Gelnique, Placebo | AbbVie | Overactive Detrusor, Neurogenic Bladder | 08/23 | 10/23 | | |
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
|
|
| Completed | 4 | 100 | Canada, US | BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA | AbbVie | Upper Facial Lines | 07/24 | 12/24 | | |
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Active, not recruiting | 4 | 393 | Europe, Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/25 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Active, not recruiting | 4 | 214 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 01/25 | 10/25 | | |
| Completed | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy |
|
|
| Active, not recruiting | 3 | 112 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine | AbbVie, Roche-Genentech | Acute Myeloid Leukemia (AML) | 09/22 | 04/25 | | |
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | AbbVie, AbbVie Inc. | Platysma Prominence | 06/23 | 06/23 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Completed | 3 | 1319 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 01/24 | 01/24 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Completed | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 3 | 1080 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine | Genmab, AbbVie | Follicular Lymphoma (FL) | 11/37 | 11/37 | | |
| Active, not recruiting | 3 | 429 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo | AbbVie | Giant Cell Arteritis (GCA) | 02/24 | 03/25 | | |
|
|
|
|
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 926 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 08/24 | | |
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence |
|
|
| Active, not recruiting | 3 | 202 | US | BOTOX, OnabotulinumtoxinA, Placebo | AbbVie | Masseter Muscle Prominence | 12/25 | 12/25 | | |
NCT06158841: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 380 | Europe, Japan, US, RoW | ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone | AbbVie | Multiple Myeloma | 12/27 | 12/27 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | Japan, US, RoW | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 3 | 1280 | Europe, Canada, Japan, US, RoW | Lutikizumab, ABT-981, Placebo | AbbVie | Hidradenitis Suppurativa | 12/26 | 12/26 | | |
| Completed | 3 | 775 | Europe, Canada, US, RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Episodic Migraine | 11/24 | 11/24 | | |
|
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
|
|
| Recruiting | 3 | 120 | Europe, US, RoW | Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab | AbbVie | Chronic Lymphocytic Leukemia | 10/26 | 10/26 | | |
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 320 | Europe, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Epkinly, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine | Genmab | Diffuse Large B-Cell Lymphoma | 01/28 | 01/28 | | |
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis |
|
|
| Active, not recruiting | 3 | 295 | Europe, Canada, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT) | AbbVie | Myelofibrosis (MF) | 02/25 | 12/26 | | |
|
|
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 675 | Europe, Canada, US, RoW | Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab | AbbVie | Atopic Dermatitis | 07/30 | 07/30 | | |
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 450 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 09/27 | 09/27 | | |
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
|
|
| Not yet recruiting | 3 | 80 | US | Mesalamine, Delzicol, Placebo | AbbVie | Ulcerative Colitis (UC) | 07/26 | 07/26 | | |
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) |
|
|
| Completed | 3 | 438 | Europe, Canada, US, RoW | Linaclotide, Placebo | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation, Irritable Bowel Syndrome With Constipation | 05/24 | 05/24 | | |
| Completed | 3 | 150 | Europe, Canada, Japan, US | Risankizumab, SKYRIZI, ABBV-066, Ustekinumab | AbbVie | Psoriasis | 02/24 | 10/24 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Completed | 3 | 161 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 10/24 | | |
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation |
|
|
| Active, not recruiting | 3 | 123 | Europe, US | Linaclotide, Placebo for Linaclotide | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 08/25 | 11/25 | | |
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 400 | RoW | YL201, Docetaxel, Capecitabine, Gemcitabine | MediLink Therapeutics (Suzhou) Co., Ltd. | Nasopharyngeal Carcinoma | 12/27 | 12/28 | | |
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 438 | RoW | YL201, topotecan hydrochloride for injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Small Cell Lung Cancer | 12/27 | 12/30 | | |
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
|
|
| Recruiting | 3 | 800 | US | Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive | AbbVie | Endometriosis | 03/29 | 06/30 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Active, not recruiting | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 04/25 | 04/25 | | |
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants |
|
|
| Completed | 3 | 159 | US | VOLITE XC, JUVÉDERM® VOLITE™ XC | AbbVie | Neck Lines | 09/24 | 09/24 | | |
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada | HArmonyCa Lidocaine Injectable Gel | Allergan | Mid Face Volume Deficit | 05/25 | 05/25 | | |
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 1399 | Europe, Canada, Japan, US, RoW | Upadacitinib, Rinvoq, ABT-494, Placebo | AbbVie | Alopecia Areata | 01/28 | 01/28 | | |
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | Telisotuzumab Vedotin, ABBV-399, Docetaxel | AbbVie | Non Small Cell Lung Cancer | 03/28 | 03/28 | | |
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars |
|
|
| Recruiting | 3 | 156 | Europe, Canada | ELAPR002f Injectable Gel, Saline Active Control | AbbVie | Atrophic Acne Scars | 02/26 | 02/26 | | |
